Loading
OnKure Therapeutics, Inc. Stock: price and insider trades · United States
No insider purchase over the last 90 days. The latest, by ACORN BIOVENTURES, L.P., was filed 19 May 2025.
OnKure Therapeutics, Inc.: what insiders have been doing
OnKure Therapeutics, Inc. is a Health Care company. Its directors and officers file their transactions with SEC (Form 4). The last twelve months, up to 23 October 2026, brought 8 filings signed by 4 insiders.
No insider bought on the market over the period, while 2 insiders filed 6 sales totalling €3,385. Leverone Jason A. filed the largest sale, €1,082, on 24 March 2026.
Compared with its exchange (3,167 companies, median 24 filings), a count of 8 filings is below the norm. Looking back to 2021, when coverage begins, insiders filed 38 purchases and 19 sales.
Typically, a trade is published a median of 2 days after it takes place. US insiders must file a Form 4 within two business days of a trade. A sale on its own says little: insiders also sell to pay tax, fund a purchase or diversify.
Elsewhere in the same sector, our signals recently picked up insider purchases at Dynavox Group AB and EssilorLuxottica. Source: insider filings from SEC (Form 4). Past trades are no guide to future returns.
Insider Decl.
90
Thresholds
n/a
Buy Volume
€31M
38 ops. · all time
Sell Volume
€5M
19 ops. · all time
Who traded when
BuySaleJason A. Leverone7 sales
Nicholas A. Saccomano7 sales
Acorn Bioventures, L.P.2 buys
Cormorant Asset Management, LP2 sales
Since the insiders bought
- +53.4%Entry US$2.32 · Close at T+365 US$3.56
- -83.9%Entry US$16.60 · Close at T+365 US$2.67
- -78.6%Entry US$84.60 · Close at T+365 US$18.10
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Financial data
as of FY 2025FY ended December 2025 · cache
US$2.36
Analyst consensus
4 analysts1.33/5
US$11.00Target US$15.50(+557%)US$21.00
Income statement
EBITDA-US$58.7M
Net income-US$59.5M0.0% margin
Valuation
PER (forward)-1.5x
P/Book0.6x
Beta0.75
Balance sheet & cash
Market capUS$95.3M
Total debtUS$549k
Free Cash Flow-US$51.9M
Debt / Equity1%
Profitability & ownership
ROE-46.9%
ROA-29.3%
% insiders10.2%
% institutions93.4%
Last declaration on 23 September 2026
Declarations90 total
302 shares@ US$2.97420.0010% mcap10.1% of flowClass A Common StockSEC:0001692747-26-000005:0
87 shares@ US$2.97420.0003% mcap10.2% of flowClass A Common StockSEC:0001609284-26-000005:0
301 shares@ US$4.156513.9% of flowClass A Common StockSEC:0001692747-26-000001:0
86 shares@ US$4.156514.0% of flowClass A Common StockSEC:0001609284-26-000001:0
5,258 shares0Class A Common StockSEC:0001622769-26-000001:0
3,911 shares0Class A Common StockSEC:0001193125-26-000942:0
302 shares@ US$2.96779.8% of flowClass A Common StockSEC:0001692747-25-000004:0
87 shares@ US$2.967710.0% of flowClass A Common StockSEC:0001609284-25-000004:0
5,545 shares0Class A Common StockSEC:0001622769-25-000003:0
4,125 shares0Class A Common StockSEC:0001193125-25-228402:0
88 shares@ US$2.62358.9% of flowClass A Common StockSEC:0001609284-25-000003:0
303 shares@ US$2.62358.7% of flowClass A Common StockSEC:0001692747-25-000003:0
6,311 shares0Class A Common StockSEC:0001415889-25-019052:0
4,694 shares0Class A Common StockSEC:0000950170-25-093063:0
88 shares@ US$2.38428.2% of flowClass A Common StockSEC:0001415889-25-018235:0
303 shares@ US$2.38428.0% of flowClass A Common StockSEC:0001415889-25-018234:0
1,129,730 shares@ US$1.8580.7% of flowCommon StockSEC:0000950170-25-074459:1
Canonical exit: 13 Aug 2025 (T+90)
270,270 shares@ US$1.85100.0% of flowCommon StockSEC:0000950170-25-074459:0
Canonical exit: 13 Aug 2025 (T+90)
1,813,439 shares@ US$1.854598.6% of flowClass A Common StockSEC:0000929638-25-001950:0
24,300 shares@ US$1.9851.4% of flowClass A Common StockSEC:0000929638-25-001870:0
1,844 shares@ US$2.6736.7% of flowClass A Common StockSEC:0001415889-25-010418:1
516 shares@ US$2.6736.3% of flowClass A Common StockSEC:0001415889-25-010419:1
1,278 shares@ US$3.327649.5% of flowClass A Common StockSEC:0001415889-25-010418:0
358 shares@ US$3.327648.8% of flowClass A Common StockSEC:0001415889-25-010419:0
2,580 shares0Class A Common StockSEC:0000950170-25-049473:0
25 of 90 declarations
About OnKure Therapeutics, Inc.
OnKure Therapeutics, Inc. is a biopharmaceutical company focused on developing innovative cancer treatments. It specializes in the discovery and development of targeted therapies to improve patient outcomes.
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations
